- Imugene (IMU) announced that cancer and research centre, City of Hope, has dosed the first patient in the phase one clinical trial of CHECKvacc
- The study is recruiting patients with triple negative breast cancer (TNBC), testing the safety and efficacy of CHECKvacc against metastatic TNBC
- Leading the trial is Yuan Yuan who says a new treatment will be “very much welcomed by both patients and the medical community”
- Imugene is trading in the grey at 45 cents per share at 3:10 pm AEDT
Imugene (IMU) has announced that cancer and research centre, City of Hope, has dosed the first patient in the phase one clinical trial of CHECKvacc.
The study is recruiting patients with triple negative breast cancer (TNBC), testing the safety and efficacy of CHECKvacc against metastatic TNBC.
TNBC is an aggressive subtype of breast cancer which affects about 20 per cent of all breast cancer patients. The cancer rapidly develops resistance to chemotherapy, which means chemotherapy advances will mostly likely not improve prognosis.
CHECKvacc is a novel chimeric orthopoxvirus with robust anti-cancer activity
including TNBC xenografts.
Leading the trial is Yuan Yuan who said a new treatment will be “very much welcomed by both patients and the medical community.”
“Oncolytic viruses such as CHECKvacc certainly hold significant potential to improve clinical response and survival, and we’re looking forward to investigating this drug in patients,” Dr Yuan said.
Commenting on the trial is Chair of Sangiacomo Family Chair in Surgical Oncology at City
of Hope Professor Yuman Fong.
“It’s a proud moment to see CF33-hNIS-antiPDL1 (CHECKvacc) continue its progression and have this phase one trial underway with patients at City of Hope,” he said.
“While we are starting the oncolytic virus in triple negative breast cancer, given the significant unmet need, it holds promise across many cancer indications.”
On the market this afternoon, Imugene was in the grey and trading at 45 cents per share at 3:10 pm AEDT.